INTRODUCTION {#SEC1}
============

Recent evidences suggest that active transposable elements (TEs) have an important role in defining Human Genome structure and function and, consequently, in controlling development and disease ([@B1],[@B2]). Short interspersed nuclear *Alu* elements (SINE) are a class of TEs highly abundant in the Human Genome that account for nearly 10% of its size ([@B3]). *Alu* retrotransposons derive from the 7SL RNA and are highly abundant in non-coding genomic regions including upstream promoters and gene introns ([@B4],[@B5]). Previous studies have shown that global transposon activity varies under diverse cellular conditions; yet, very little is known regarding the mechanisms through which TEs regulate the expression of specific genes ([@B6]). In this context, a recent study revealed that an *Alu* element inserted in human chromosome 9p21 within the long non-coding RNA (lncRNA) *ANRIL* was needed to *trans*-regulate genes presumably involved in atherosclerosis ([@B7]). In the mouse, *Anril* lncRNA regulated cell proliferation and differentiation through the *Cdkn2A/B* gene ([@B8]).

Notably, TEs are potential carriers of binding sites for transcription factors. Genome-wide analyses have found an enrichment of binding sites for ESR1, TP53, OCT4 (POU5F1), SOX2 and CTCF in human TEs ([@B9]). In fact, TEs provide up to 25% of the binding sites for the pluripotency regulators OCT4 (POU5F1) and NANOG and for the chromatin remodeler CTCF in both human and mouse embryonic stem (ES) cells ([@B10]). Consequently, it appears plausible that TEs assume an important role in the control of transcriptional programs that regulate cell turnover and plasticity ([@B10]). Furthermore, certain classes of TEs were upregulated whereas others were downmodulated during the reprogramming of differentiated cells into induced pluripotent stem (iPSc) cells, thus producing an expression profile reminiscent of that of ES cells ([@B12],[@B13]). Overall, these former studies suggest that TEs could modulate specific transcriptional programs that drive pluripotency and cell reprogramming ([@B12]). Previous work from our laboratory identified a novel B1-SINE retrotransposon (B1-X35S) widely represented in upstream regulatory regions of the mouse genome that acts as a genomic insulator blocking target gene expression ([@B14],[@B15]). B1-X35S-dependent insulation required the interaction of transcription factors dioxin receptor (AhR) and Slug (Snai2) with their consensus sequences present in B1-X35S and the transcriptional activity of RNA polymerases III and II ([@B15],[@B16]).

It is becoming increasingly clear that some repetitive elements are relevant for cell functioning. Recent efforts have identified repetitive sequences with the potential to regulate gene expression and to participate in the control of specific cell processes under normal and pathological conditions ([@B15],[@B17]). In this work, we have investigated the functional relevance of *Alu* retrotransposons regulated by the dioxin receptor AHR in the differentiation of human embryonic carcinoma cells. We have focused on individual *Alu* elements located in the upstream regulatory regions of pluripotency genes *NANOG* and *OCT4*. AHR exerted a pro-differentiation role that was responsible, at least in part, for the repression of *OCT4* and *NANOG*. Interestingly, such repressive mechanism appears to be mediated by non-coding RNA transcripts produced by RNA polIII from the *Alu* elements following AHR binding. In fact, the *NANOG Alu* was able to repress the expression of both *OCT4* and *NANOG* in the absence of a differentiating stimulus. Among the mechanisms that could repress *NANOG* and *OCT4* in differentiated carcinoma cells, processing and loading of *NANOG Alu*-derived transcripts into the miRNA machinery appears as a plausible possibility. In sum, we suggest that individual *Alu* retrotransposons could have a causal role in the control of complex cellular functions such as differentiation and pluripotency. The regulatory mechanism proposed here could also contribute to establish gene expression programs required for cellular reprogramming and for the maintenance of an undifferentiated state.

MATERIALS AND METHODS {#SEC2}
=====================

Antibodies {#SEC2-1}
----------

The following antibodies were used: βIII-tubulin (Santa Cruz Biotechnology sc-58888, clone TUJ-1), GAP43 (Millipore AB-5220), Tau (generous gift of Dr Lorenzo-Benayas, University of Extremadura), GAPDH (Cell Signaling 2118, clone 14C10), OCT4 (Santa Cruz Biotechnology sc-5279, clone C-10), NANOG (AbCam Ab-21624), AGO2 (Millipore 03--110), AHR (ENZO Life Sciences BML-SA210 and Immunostep 130605--1) and β-Actin (Sigma A2066).

Cells lines and reagents {#SEC2-2}
------------------------

Human embryonic teratocarcinoma NTERA-wt and NTERA-sh cells were cultured in DMEM containing 10% FBS, 100 U/ml penicillin, 100 μg/ml streptomycin and 2 mM L-glutamine at 37°C and 5% CO~2~ atmosphere. NTERA-wt and NTERA-sh cell lines were authenticated by DNA profiling using 8 different and highly polymorphic short tandem repeat (STR) loci (German Biological Resource Centre DSMZ). H9 human ES cells were cultured in matrigel-coated culture plates in high glucose Dulbecco\'s modified Eagle\'s medium (DMEM) knockout medium containing knockout serum replacement, L-glutamine and non-essential aminoacids at 37°C in a 5% CO~2~ atmosphere. Cells were tested to be mycoplasma free using the LookOut Mycoplasma detection kit (Sigma). Protein A/G-plus agarose was from Santa Cruz Biotechnology. The iScript™ Reverse Transcription Supermix was from Bio-Rad and the SYBR^®^ Select Master Mix was from Life Technologies. The AhR agonist 6-formylindolo\[3,2-b\]carbazole (FICZ) was from Enzo.

Retroviral knockdown of human AHR {#SEC2-3}
---------------------------------

AHR was knocked-down in NTERA cells by retroviral transduction essentially as described ([@B20],[@B21]) using the sh-RNA sequence 5′ TGCTGTTGACAGTGAGCGAGCA

ATGAATTTCCAAGGGAAGTAGTGAAGCCACAGATGTACTTCCCTTGGAAATTCATTGCCTGCCTACTGCCTCGGA 3′. For rescue experiments, an shRNA was synthesized targeting the 3′UTR region of the human AHR: 5′ TGCTGTTGACAGTG

AGCGAACTCTTTACCTTTATTGATATTAGTGAAGCCACAGATGTAATATCAATAAAGGTAAAGAGTGTGCCTACTGCCTCGGA 3′. shRNAs sequences were designed using the algorithm available at: <http://www.stanford.edu/group/nolan/retroviral_systems/retsys.html>.

Bioinformatic analysis of *Alu* elements containing AHR binding sites {#SEC2-4}
---------------------------------------------------------------------

The Human Genome was analyzed for the presence of conserved elements containing an XRE site and an E-box using the algorithm previously described ([@B14]). Two of the most abundant groups of elements (e.g. X36S and X45S) were analyzed for their presence in the 5′promoter region of pluripotency and stemness genes within a 200-bp interval from the transcription start site. The background expression of *NANOG* and *OCT4 Alu*s was estimated by referring the RNA Seq data under basal cell conditions (untreated NTERA-wt cells) to the total number of *Alu*Sq and AluSx elements identified in the Human Genome.

Chromatin immunoprecipitation (ChIP) {#SEC2-5}
------------------------------------

Chromatin immunoprecipitation (ChIP) and double-sequential ChIP for AHR and OCT4 binding to the *NANOG* and *OCT4* Alus were performed in NTERA-wt cells essentially as described ([@B15],[@B22]). NTERA-sh cells were used as negative controls for ChIP experiments.

RNA immunoprecipitation (RIP) {#SEC2-6}
-----------------------------

RNA immunoprecipitation (RIP) for *NANOG Alu*-T1 and *Alu*-T2 loading into AGO2 was done essentially as described ([@B23]). Briefly, NTERA-wt cells were lysed in polysome lysis buffer containing RNase and protease inhibitors. Pre-washed protein-A/G plus agarose was incubated overnight at 4°C with 5 μg anti-AGO2 antibody or the same amount of IgG. After washing, the mRNP lysate was added and the mix briefly centrifuged to obtain the input fraction in the supernatant. Reactions were then gently rotated at room temperature for 2 h, washed and incubated for 30 min in NT2 buffer containing sodium dodecyl sulphate and proteinase K. RNA was phenol-chloroform-isoamyl alcohol extracted and ethanol precipitated. RIP was analyzed by qPCR using the oligonucleotides indicated in Supplementary Table S1. Polymerase chain reaction (PCR) reactions were also analyzed in agarose gels to determine the presence of the expected product.

RNA sequencing (RNAseq) {#SEC2-7}
-----------------------

RNA sequencing (RNAseq) was performed in NTERA-wt and NTERA-sh cells in presence or absence of 1 μM RA. Libraries were made using RNA molecules of 75--250 bases in length isolated from agarose gels. Libraries were sequenced in an Illumina MiSeq equipment, which produced 8.32, 5.92, 7.70 and 8.79 million lectures for NTERA-wt (UT), NTERA-wt (RA), NTERA-sh (UT) and NTERA-sh (RA), respectively. FASTQ raw reads were transformed into FASTA format using a custom Perl script available on request. These 75-bp FASTA reads were integrated into a database, and NCBI Blast was applied using *OCT4* and *NANOG Alu* full-length sequences as query. Search parameters were adjusted for the detection of sequences with the highest similarity, and normalized against the values obtained for standard *Alu* elements. When the analysis of identical sequences was required, ad hoc Perl scripts comparing specific sequences against the full Human Genome sequence were used.

Synthesis and cloning of *NANOG* and *OCT4 Alu*s and 3′UTR sequences {#SEC2-8}
--------------------------------------------------------------------

Wild-type *NANOG* and *OCT4 Alu* elements and *NANOG Alu*s mutated in the XRE site and/or A + B boxes were synthesized by GenScript and cloned in the promoter-less pUC57 vector. *NANOG* mRNA 3′UTR was amplified using the primers indicated in Supplementary Table S1 and cloned in the pGL2-Basic-Luc vector. *NANOG* 3′UTR mutants lacking the homology sequences for *Alu*-T1 and/or *Alu*-T2 were constructed by PCR from the wild-type sequence and cloned in the pGL2-Basic-Luc vector. The pUC57 vector does not contain any promoter and it is therefore indicated to assay the endogenous transcription of *NANOG* and *OCT4 Alu*s by RNA polIII.

Mouse teratoma induction {#SEC2-9}
------------------------

Swiss male immunodeficient mice at 8--10 weeks of age (Charles Rives) were used for teratoma induction. Mice experimentation was approved and followed the regulation established by the Bioethics and Biosecurity Commission of the University of Granada. Teratoma assays were performed as described previously ([@B24]). Briefly, aliquots of 10^6^ exponentially growing NTERA-wt and NTERA-sh cells were injected subcutaneously in the flank of the neck of each mouse. Two experiments of two mice were done for each cell line. After 7--8 weeks, the mice were killed and the tumors extracted, fixed in buffered formalin, embedded in paraffin and sectioned. Sections were stained with antibodies for the three germinal layers: endoderm (pan-cytokeratins and α-fetoprotein), mesoderm (α-smooth muscle actin) and ectoderm (acidic fibrilar acidic protein). Immunohistochemistry sections were analyzed blinded by eight different investigators and the intensity of staining estimated on a 0--10 scale.

Transient transfection {#SEC2-10}
----------------------

*NANOG* and *OCT4 Alu* transposons, DROSHA and DGCR8 dominant negative mutants ([@B25]) and *NANOG* 3′UTR plasmids were purified and transiently transfected in NTERA-wt or NTERA-sh cells using FuGene 6 (Promega). Aliquots of 1 μg DNA were used for the transfections essentially as described ([@B14]). Transfection continued for 48 h in experiments analyzing the expression of *NANOG* and *OCT4 Alu*s or for 36 h in luciferase activity assays. H9 cells were transiently transfected with the AHR sh-RNA sequence indicated above using the Human Stem Cell Nucleofector kit in an Amaxa equipment (A-23 program) following the recommendations of the manufacturer.

Luciferase activity assays {#SEC2-11}
--------------------------

*NANOG* 3′UTR constructs were amplified by RT-PCR from cellular RNA using the oligonucleotides indicated in Supplementary Table S1. The amplified 3′UTR was cloned in the XhoI-KpnI sites of the pGL2-Basic vector containing the firefly luciferase gene. This 3′UTR sequence was further modified by PCR to delete the homology region for *NANOG Alu*-T1, *Alu*-T2 or both. 3′UTR constructs were co-transfected with the pRLTK (renilla luciferase) vector to normalize luciferase activity. Firefly and renilla luciferase activities were measured after 36 h using the Dual Glow kit (Promega) in a Varioskan Flash luminometer (Thermo).

Nuclear and cytosolic cell extracts and immunoblotting {#SEC2-12}
------------------------------------------------------

Sodium dodecyl sulphate-polyacrylamide gel electrophoresis and immunoblotting were performed using NTERA-wt and NTERA-sh cell extracts as indicated ([@B21]). Nuclear and cytosolic cellular extracts were prepared from both cell lines as described ([@B26]).

Immunofluorescence {#SEC2-13}
------------------

Immunofluorescence was done in an Olympus FV1000 confocal microscopy on cultures fixed for 20 min at room temperature in 4% paraformaldehyde (Polysciences Inc.). Fluorochromes used were Alexa 488 (NANOG, OCT4, βIII-tubulin) and Alexa 633 (AHR, Tau and GAP43). DAPI was used to stain cell nuclei. Fluorescence distribution was analyzed using the FV10 software (Olympus).

Reverse transcription and real-time RT-qPCR {#SEC2-14}
-------------------------------------------

Total RNA was isolated from NTERA-wt and NTERA-sh cells using the RNeasy kit (Qiagen). Reverse transcription was performed with random hexamers and the iScript™ Reverse Transcription Supermix (Bio-Rad). qPCR was done using SYBR^®^ Select Master Mix (Life Technologies) in a Step One equipment (Life Technologies). The oligonucleotides used for RT-qPCR are indicated in Supplementary Table S1. Conventional (no quantitative PCR) was done using Biotaq DNA polymerase in a Bio-Rad T100 equipment.

Clone formation assay {#SEC2-15}
---------------------

Clonogenic assays in 2D were done by platting 103 NTERA-wt and NTERAsh cells in 35 mm plain tissue culture dishes basically as described ([@B20]). After 7 days, the medium was removed and clones washed in PBS, photographed and counted using the ImageJ software (version 1.45S).

Flow cytometry {#SEC2-16}
--------------

The analysis and separation of cancer stem-like cells in NTERA-wt and NTERA-sh cultures was done in a MoFlo-XDP equipment (Beckman-Coulter) essentially as described ([@B20]). Both cell lines were stained for 10 min at 10°C with antibodies specific for CD133^+^ (CD133-PE), CD44^+^ (CD44-PerCP) and CD29^+^ (CD29-FITC). To-Pro (0.1 μM) was used to discriminate dead cells from the analyses. Cell cycle distribution was determined essentially as described ([@B27]).

Sphere formation assay {#SEC2-17}
----------------------

NTERA-wt and NTERA-sh cells were plated in Nunc ultra-low adherence 24-well plates (Thermo Fisher) at 3 × 10^4^ cells/well and spheres allowed to form for 24 h. Images were acquired with an Olympus Cell-R microscope and sphere number and size quantified using the ImageJ software (version 1.45S).

Transposition assays {#SEC2-18}
--------------------

For transposition assays, 2 × 10^4^ cells/35 mm^2^ plate were co-transfected with the driver vector pCEPL1SM-NN (containing a LINE-1) and the pBSKS-NeoIII vector harboring the NANOG or the OCT4 *Alu* elements. Transfectants were selected by culturing with 400 μg/ml G418 for 12--13 days.

DNA sequencing {#SEC2-19}
--------------

NANOG *Alu*-T1 and *Alu*-T2 ncRNA transcripts were sequenced using the oligonucleotides indicated in Supplementary Table S1 in an Applied Biosystems 3130 automatic capillary sequencer.

Statistical analyses {#SEC2-20}
--------------------

Comparison between experimental conditions was done using GraphPad Prism 6.0 software (GraphPad). Unpaired two-sided Student\'s *t*-test was used to analyze differences between two experimental groups. Differences between three or more experimental conditions were analyzed using ANOVA. Data are shown as mean ± SD. Differences were considered significant at \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001. Data analyses are indicated in the figure legends.

RESULTS {#SEC3}
=======

AHR knockdown leads to an undifferentiated phenotype and blocks RA-induced differentiation of human carcinoma cells {#SEC3-1}
-------------------------------------------------------------------------------------------------------------------

To investigate the implication of AHR in cell differentiation, we have used human pluripotent embryonic teratocarcinoma NTERA2 cells (NTERA) because they can be differentiated in culture by the addition of the endogenous molecule retinoic acid (RA) and because they can be genetically engineered to modulate target gene expression ([@B28]). Consistent with their pluripotent phenotype, treatment of NTERA cells growing at low cell density with RA produced highly compact clones (Figure [1A](#F1){ref-type="fig"}) having increased expression of the neuronal markers Tau, βIII-tubulin and GAP43 (Figure [1B](#F1){ref-type="fig"} and [C](#F1){ref-type="fig"}). This differentiation phenotype of NTERA cells is consistent with that reported in previous studies ([@B29]). Notably, total cellular levels of AHR significantly increased during RA-induced differentiation of NTERA cells (Figure [1D](#F1){ref-type="fig"}), suggesting a role for this receptor in the process. To test this hypothesis, we used retroviral transduction to stably knockdown AHR expression in NTERA cells by means of short hairpin RNAs (NTERA-sh). This experimental approach was very efficient in reducing AHR protein to very low levels in basal and RA-treated cells (Figure [1D](#F1){ref-type="fig"}). To avoid caveats derived from the use of retrovirally-transduced cells, we decided to work with a pool of NTERA cells after puromycin selection rather than using individual interfered clones. AHR depletion produced spread clones (Figure [1A](#F1){ref-type="fig"}) with a significant reduction in the expression of neuronal markers Tau, βIII-tubulin and GAP43 (Figure [1B](#F1){ref-type="fig"} and [C](#F1){ref-type="fig"}). Moreover, AHR depleted cells had an almost negligible response to RA-induced differentiation (Figure [1A--C](#F1 F1){ref-type="fig"}). The undifferentiated phenotype caused by AhR downmodulation in basal and RA-treated NTERA cells was not associated with significant changes in cell cycle distribution as determined by FACS analysis (Supplementary Figure S1A). Previous reports have shown that AHR depletion could be relevant for mouse ES cell maintenance ([@B31]) and for mouse melanoma cells to develop an undifferentiated and metastatic phenotype ([@B20],[@B32]). In agreement, AHR-depleted NTERA-sh cells had increased levels of stem-like markers CD44^+^/CD133^+^/CD29^+^, more potential to form spheres under low attachment growing conditions and reduced levels of differentiation-related dehydrogenase activity than wild-type NTERA cells (Supplementary Figure S1B--G). Altogether, these data suggest that AHR is involved in NTERA differentiation.

![AHR knockdown impairs RA-induced differentiation. (**A**) NTERA-wt and AHR knockdown NTERA-sh cells were grown in 2D cultures and clone formation analyzed 48 h later in absence (UT) or presence of 1 μM RA. (**B**) Both cell lines were left untreated (UT) or treated with 1 μM RA for 48 h. Total cell extracts were analyzed for the expression of neuronal markers Tau, βIII-tubulin and GAP43 by immunoblotting. GAPDH was used to normalize protein expression. (**C**) Tau, βIII-tubulin and GAP43 were also analyzed by immunofluorescence in untreated (UT) or RA-treated NTERA-wt and NTERA-sh cells using a Fluoview FV1000 confocal microscope. (**D**) NTERA-wt and NTERA-sh cells were left untreated or treated with 1 μM RA for 72 h and total AHR protein levels determined by immunoblotting. β-Actin was used as normalization control. Panels A--D: *n* = 4 biological replicates. \**P* \< 0.05 and \*\**P* \< 0.01. Data are shown as mean ± SD.](gkw095fig1){#F1}

Differentiation promotes AHR nuclear accumulation and represses pluripotency genes *OCT4* and *NANOG* {#SEC3-2}
-----------------------------------------------------------------------------------------------------

We next explored if the differentiation-dependent increase in AHR levels could lead to changes in its intracellular distribution. RA treatment promoted a robust nuclear accumulation of AHR in NTERA-wt cells (Figure [2A](#F2){ref-type="fig"} and [B](#F2){ref-type="fig"}) but had a negligible effect in AHR-interfered cells, which maintained their very low basal levels of AHR (Figure [2A](#F2){ref-type="fig"} and [B](#F2){ref-type="fig"}). To further analyze the implication of AHR in RA-induced differentiation, we performed long-term RA treatment (e.g. 4 weeks) of NTERA-sh cells. Under persistent differentiating conditions, AHR protein levels gradually increased and NTERA-sh cells acquired wild-type-like clone morphology and the expression of neuronal markers Tau and βIII-tubulin (Supplementary Figure S2A and B). Restoration of a differentiation response in NTERA-sh cells by AHR re-expression supports a role for AHR in preserving teratocarcinoma cell differentiation.

![RA-induced differentiation translocates AHR to the cell nucleus and represses OCT4 and NANOG. (**A**) NTERA-wt and NTERA-sh cells were left untreated or treated with 1 μM RA for 72 h. Cytosolic and nuclear extracts were prepared and analyzed for the presence of AHR in each cellular compartment by immunoblotting. GAPDH and RNA polIII were used as cytosolic and nuclear controls, respectively. (**B**) The intracellular distribution of AHR was determined by immunofluorescence in NTERA-wt and NTERA-sh cells left untreated or treated with 1 μM RA for 72 h in absence (UT) and presence of 1 μM RA. (**C** and **D**) *NANOG* and *OCT4* mRNAs were quantified by RT-qPCR in both cell lines left untreated (UT) or treated with 1 μM RA for 48 or 72 h. *GAPDH* mRNA was used to normalize gene expression (ΔCt) and 2^−ΔΔCt^ to calculate variations with respect to control or untreated conditions. (**E**) OCT4 protein levels were analyzed by immunoblotting and normalized by GAPDH. (**F**) The effects of RA on OCT4 and NANOG protein expression were also determined in NTERA-wt and NTERA-sh cells by immunofluorescence. Panels A--D: *n* = 4 biological replicates; panels E--F: *n* = 6, two technical replicates in three biological replicates. \**P* \< 0.05 and \*\**P* \< 0.01. Data are shown as mean ± SD.](gkw095fig2){#F2}

To address that hypothesis, we first analyzed whether the effects of AHR on cell differentiation were mediated by changes in the expression of pluripotency genes. RA treatment of NTERA-wt cells produced a large reduction in mRNA levels of the stemness-related genes *NANOG* and *OCT4* (Figure [2](#F2){ref-type="fig"} C and D, and Supplementary Figure S3A and B) without a significant effect on *SOX2* and *NOTCH1* (Supplementary Figure S3C and D). In agreement, protein levels of OCT4 and NANOG were also reduced by RA treatment in NTERA-wt cells as determined by fluorescence confocal microscopy and western-blot analyses (Figure [2E](#F2){ref-type="fig"} and [F](#F2){ref-type="fig"}). In contrast, NTERA-sh cells had increased levels of OCT4 and NANOG mRNA and protein under basal conditions and, importantly, they were less sensitive to RA treatment (Figure [2C--F](#F2 F2){ref-type="fig"}). To further support the implication of AHR in OCT4 and NANOG repression, we did treatments with the AHR ligand 6-formylindolo\[3,2-b\]carbazole (FICZ) in absence of RA ([@B33]). FICZ decreased *OCT4* and *NANOG* mRNA levels in untreated NTERA-wt cells (Supplementary Figure S3E and F) but not in NTERA-sh cells (Supplementary Figure S3G and H), suggesting that AHR is involved in the mechanism that regulates OCT4 and NANOG during the differentiation of human carcinoma cells.

Pluripotency genes contain *Alu* retrotransposons in their upstream regulatory regions that are transcribed upon differentiation {#SEC3-3}
--------------------------------------------------------------------------------------------------------------------------------

Bioinformatic analyses have identified thousands of potential AHR binding sites (XRE; Xenobiotic Responsive Element) dispersed throughout the Human Genome ([@B14],[@B16],[@B34]). However, their functional and biological significance remains to be determined. Using a previously developed Perl script ([@B14]), we have identified XRE sites for AHR binding that happen to be included within repetitive sequences that are located in the promoter of pluripotency genes *NANOG, OCT4, SOX2* and *KLF4*. These repetitive elements have been assigned to the family of *Alu-S* retrotransposons having an XRE / E-box motif similar to that found in murine SINE-B1 repeats ([@B14]) (Figure [3A](#F3){ref-type="fig"}). *Alu* elements in the *NANOG, SOX2* and *KLF4* promoters belong to the *Sx* subfamily whereas the *OCT4-Alu* is included in the *Sq* subfamily of human retroelements (Figure [3A](#F3){ref-type="fig"}). Importantly, these *Alus* contain A and B boxes and a putative transcription start site for RNA polymerase III (RNA polIII)-dependent transcription and at least one XRE site for AHR binding (Figure [3B](#F3){ref-type="fig"}, *NANOG* and *OCT4 Alus* are shown). This sequence analysis suggested that these *Alu*s could control the expression of their hosting genes through the transcription factor AHR.

![Human *OCT4* and *NANOG* genes contain *Alu* retrotransposons in their promoters harboring AHR and RNA polIII binding sites. (**A**) Sequence analysis was used to determine the distribution of *Alu* retrotransposons among the *Alu-Sx* (*NANOG, SOX2* and *KLF4*) or *Alu*-Sq (*OCT4*) subfamilies. (**B**) The full-length sequences of *NANOG-Alu*-Sx and *OCT4-Alu*-Sq were analyzed for the presence of XRE sites for AHR binding and A and B boxes for RNA polIII-dependent transcription. A DR2 box was also found in the *NANOG-Alu. OCT4* and *NANOG Alu*s contained the putative +1 adenosine nucleotide for RNA polIII transcription. The algorithm used for the bioinformatics analysis has been described ([@B14]). (**C**) Non-coding RNA libraries were prepared and sequenced as indicated in Supplementary Figure S4A. The bulk of reads obtained from each library was aligned with the sequences of *OCT4* and *NANOG Alu*s. Transcripts frequently expressed in NTERA-wt (blue) or NTERA-sh (red) in absence (UT) or presence of 1 μM RA appeared as peaks overlapping the sequence of each *Alu* element. The baseline expression of human *Alu*Sq and *Alu*Sx transposons is indicated by a horizontal black dotted line. (**D**) The sense (red line) and antisense (black line) orientation of the transcripts produced from the *NANOG* and *OCT4 Alus* was determined from the RNAseq dat. Transcripts showing complementary for either the sense or the antisense strand were plotted against the full-length *Alus* to produce peaks corresponding to the *NANOG Alu*-T1 and *Alu*-T2 and *OCT4 Alu*-T molecules.](gkw095fig3){#F3}

We considered the possibility that transcription of the *Alu* elements present in the promoter of these pluripotency genes could repress their expression to induce differentiation of carcinoma cells. We focus our study on *NANOG* and *OCT4* since they were the genes more significantly affected by RA treatment in NTERA cells in an AHR-dependent manner (see Supplementary Figure S3). Transcription of *Alu* retrotransposons was analyzed by deep sequencing of small RNA molecules (RNAseq) isolated from NTERA-wt and NTERA-sh cells under basal and RA-differentiated conditions. Raw RNAseq data have been deposited in the Sequence Read Archive (SRA, NCBI) with submission number PRJNA301447. Previous work has shown that RNAseq is a useful tool to identify transcripts produced from individual *Alu* elements by RNA polIII ([@B35]). To avoid sequencing mRNAs and long non-coding RNA transcripts, libraries were made using size-selected small RNA populations (Supplementary Figure S4A, ncRNA). Bioinformatic alignment of the RNAseq data against *OCT4* and *NANOG Alus* identified transcripts produced from the *OCT4-Alu* (hereafter *OCT4 Alu*-T) and *NANOG-Alu* (hereafter *NANOG Alu*-T1 and *Alu*-T2) under basal conditions in NTERA-wt cells (Figure [3C](#F3){ref-type="fig"}). Notably, the level of those transcripts was significantly increased by RA-induced differentiation in NTERA-wt cells but not in NTERA-sh cells (Figure [3C](#F3){ref-type="fig"}). Importantly, the level of *NANOG* and *OCT4 Alu*-derived transcripts was significantly higher than the predicted background level between *AluSq* and *AluSx* elements (Figure [3C](#F3){ref-type="fig"}, black dotted line). We have previously found that transcription of an AhR-regulated murine SINE-B1 retrotransposon takes place mainly in the antisense orientation ([@B15]). Similarly, the analysis of RNAseq data indicated that both *OCT4* and *NANOG Alus* were preferentially transcribed in the antisense direction, despite the presence of sense transcripts produced from the *NANOG Alu* (Figure [3D](#F3){ref-type="fig"}).

AHR and RNA polIII are involved in *OCT4* and *NANOG* repression in differentiated carcinoma cells {#SEC3-4}
--------------------------------------------------------------------------------------------------

Most human *Alu*s are transcribed by RNA polIII, which can be inhibited by the molecules tagetitoxin (TGT) ([@B36]) and WYE132 ([@B37]). TGT treatment significantly blocked the repression of *NANOG* and *OCT4* produced by RA at the mRNA level in NTERA-wt cells (Figure [4A](#F4){ref-type="fig"}). Control experiments showed that TGT was a potent RNA polIII inhibitor in NTERA cells able to efficiently inhibit *Leu* tRNA expression (Figure [4B](#F4){ref-type="fig"}). In addition, NTERA-wt cells had a similar response to WYE132, which could also efficiently block the repression of *NANOG* and *OCT4* by RA (Supplementary Figure S4B). WYE132 was an RNA polIII inhibitor in NTERA cells since it could repress *Leu* tRNA expression (Supplementary Figure S4C) without significantly affecting *NANOG* and *OCT4* mRNAs in the absence of RA treatment (e.g. WYE132 did not inhibit RNA polII) (Supplementary Figure S4D). Thus, *NANOG* and *OCT4* repression in differentiated NTERA cells appears to require AHR upregulation and the transcriptional activation of their *Alu* elements by RNA polIII. In agreement with such possibility, sequence analysis revealed that *OCT4* and *NANOG Alu*s contain the core motifs present in most active *Alu*S subfamilies (Supplementary Figure S4E) ([@B17]). Furthermore, both *NANOG* and *OCT4 Alus* were able to retrotranspose in HeLa cells as determined using an established *Alu* engineered assay ([@B25],[@B38]) (data not shown).

![*OCT4* and *NANOG Alus* bind AHR, are transcribed by RNA polIII in differentiated cells. (**A**) *NANOG* and *OCT4* mRNA levels were quantified in NTERA-wt cells left untreated (UT), treated with 1 mM RA or with 1 mM RA + 10 mM tagetitoxin (TGT) for 48 h. (**B**) *Leu* tRNA levels were measured in NTERA-wt cells untreated (UT) or treated with 1 mM RA + 10 mM TGT for 48 h. (**C**) Chromatin immunoprecipitation (ChIP) for AHR and OCT4 binding to the *NANOG* and *OCT4 Alus* was done in NTERA-wt cells left untreated (UT) or treated with 1 μM RA for 48 h. For specificity, one primer for the PCR reaction to amplify each *Alu* was located in a unique genomic sequence flanking the transposon (see Supplementary Table S1). Double ChIPs involved a first immunoprecipitation with anti-OCT4 followed by a second immunoprecipitation with anti-AHR antibody. NTERA-sh cells were used as negative controls. Input DNAs and immunoprecipitations done in absence of specific antibodies were also performed. (**D** and **E**) *NANOG* and *OCT4 Alu*-derived transcripts were quantified by RT-qPCR in absence (UT) or presence of 1 μM RA using the conditions described in Supplementary Figure S5A-C. (**F**) Basal levels of *NANOG Alu*-T1 and *Alu*-T2 and *OCT4 Alu*-T were measured in NTERA-wt cells by RT-qPCR. *GAPDH* mRNA was used to normalize gene expression (ΔCt) and 2^−ΔΔCt^ to calculate variations with respect to control or untreated conditions. Panels A and B: *n* = 6, two technical replicates in three biological replicates; panel C: *n* = 4 biological replicates; panels D-F: *n* = 4, two technical replicates in two biological replicates. \**P* \< 0.05, \*\**P* \< 0.01 and \*\*\**P* \< 0.001. Data are shown as mean ± SD.](gkw095fig4){#F4}

As AHR is a transcription factor, we next tested if the repression of *NANOG* and *OCT4* required AHR binding to the XRE sequences present in their upstream *Alu* elements (Figure [3B](#F3){ref-type="fig"}). ChIP experiments in NTERA-wt cells using genomic region-specific primers showed that, under basal conditions, AHR was present in the *OCT4 Alu* but not in the *NANOG Alu* (Figure [4C](#F4){ref-type="fig"}). Upon RA-induced differentiation, AHR was recruited to the *NANOG-Alu* and released from the *OCT4 Alu* (Figure [4C](#F4){ref-type="fig"}). Interestingly, sequential double AHR + OCT4 ChIP revealed that OCT4 and AHR were recruited together to the *NANOG-Alu* in RA-differentiated NTERA-wt cells (Figure [4C](#F4){ref-type="fig"}). A negligible interaction of AHR with the *NANOG-Alu* (Figure [4C](#F4){ref-type="fig"}) or the *OCT4 Alu* (not shown) was found in basal or RA-treated NTERA-sh cells. These results indicate that AHR binds to the *NANOG Alu* in differentiated cells and that AHR could be part of a transcriptional complex that also includes OCT4.

The *NANOG* and *OCT4 Alu* elements are transcribed during differentiation {#SEC3-5}
--------------------------------------------------------------------------

Based on the apparent prevalence of defined transcripts in differentiated NTERA cells (Figure [3C](#F3){ref-type="fig"}), we next used the RNAseq data to assess which amplicons may be used to detect the expression of *NANOG* and *OCT4* Alus. Considering the repetitive nature of *Alu* elements, we first interrogated the Human Genome for the presence of instances identical to either *NANOG* or *OCT4 Alus*. At the current sequence resolution of the Human Genome, we did not find any other *Alu* elements fully homologous to those present in *NANOG* and *OCT4* promoters. Based on this finding, we then decided to map putative sites in the Human Genome having full sequence identity with the transcripts produced from the *NANOG* and *OCT4 Alus*. This approach would give us an accurate estimation on to what extent those transcripts were produced from the *NANOG* and *OCT4 Alus* (since both elements appear at unique locations in the Human Genome) and not from other related retrotransposons. Interestingly, the amplicons predicted by RNA-seq analysis (Figure [3C](#F3){ref-type="fig"}) were also unique in the Human Genome for the case of *NANOG Alu*-T1 and *Alu*-T2 in chromosome 12 (Figure [5](#F5){ref-type="fig"}, full length hit and asterisks) and *OCT4 Alu*-T in chromosome 6 (Figure [5](#F5){ref-type="fig"}, full length hit and asterisks). Moreover, NCBI Blast analysis predicted partial sequence similarity with only 10 and 21 more *Alu* elements for *NANOG Alu*-T1 and *Alu*-T2 and with 214 more *Alu* elements in the case of *OCT4*, respectively (Figure [5](#F5){ref-type="fig"}). Based on these results, transcript-specific RT-qPCR assays were designed to quantify the expression of *OCT4*- and *NANOG-Alu*-derived transcripts (Supplementary Figure S5A and B). Amplicons were selected to cover the T1 (yellow) and T2 (red) transcripts from the *NANOG Alu* and the T (cyan) transcript from the *OCT4 Alu* (Supplementary Figure S5C). Capillary fluorescent dideoxi-sequencing was used to confirm the identity of the amplicons obtained by qPCR (Supplementary Figure S5D). The results obtained indicated that *NANOG Alu*-T1 and *Alu*-T2 (Figure [4D](#F4){ref-type="fig"}) and *OCT4 Alu*-T (Figure [4E](#F4){ref-type="fig"}) were significantly upregulated by RA in NTERA-wt but not in NTERA-sh cells. In addition, the *OCT4 Alu*-T was expressed at much lower levels than the *NANOG Alu*-T1 and *Alu*-T2 under basal cell conditions (Figure [4F](#F4){ref-type="fig"}). Moreover, treatment with TGT or WYE132 reduced the levels of *OCT4 Alu*-T, *NANOG Alu*-T1 and *Alu*-T2 transcripts in untreated NTERA-wt cells, further supporting the implication of RNA polIII in the transcription of *OCT4* and *NANOG* Alus (Supplementary Figure S5E).

![Full length *NANOG* and *OCT4 Alu*-derived transcripts map to their specific genomic locations. The complete sequence of the *NANOG Alu*-T1 and *Alu*-T2 and *OCT4 Alu*-T transcripts were aligned against the Human Genome to identify their fully homologous locations in each chromosome (100% sequence homology, full length hit, asterisk). Full length *NANOG Alu*-T1 and *Alu*-T2 map to chromosome 12 whereas full length *OCT4 Alu* map to chromosome 6. A similar analysis was done reducing the percentage of sequence homology of each *Alu*-derived transcript and the Human Genome (partial hit).](gkw095fig5){#F5}

We next investigated the role of AHR in *OCT4* and *NANOG* transcription. As a first approach, we treated NTERA cells with the AHR non-toxic ligand FICZ. AHR activation by FICZ increased the levels of *NANOG Alu*-T1 and *Alu*-T2 and *OCT4 Alu-T* transcripts in NTERA-wt cells (Supplementary Figure S6A--C), supporting a role for this receptor in the regulation of these non-coding RNA transcripts. The effect was transient and each *Alu*-derived transcript returned to its basal level 24 h after FICZ treatment (Supplementary Figure S6A--C). Consistently, ChIP experiments showed that FICZ was able to induce AHR binding to the *NANOG Alu* in NTERA-wt cells to a level similar to that produced by RA treatment (Supplementary Figure S6D). Surprisingly, FICZ was also a potent inducer of OCT4 binding to the *NANOG Alu*, reaching levels significantly higher that those obtained by RA (Supplementary Figure S6D).

We then decided to rescue AHR expression in AHR knockdown cells to investigate if restoring AHR could increase the content in *Alu*-derived transcripts while reducing the levels of *NANOG* and *OCT4* mRNAs (Figure [6](#F6){ref-type="fig"}). To do that, NTERA-wt cells were retrovirally engineered to stably express an shRNA molecule targeting the 3′UTR of the human AHR (NTERA-sh 3′UTR); this approach allowed transfection of a human AHR coding sequence not targeted by the 3′UTR shRNA molecule (Supplementary Table S1). NTERA-sh 3′UTR cells had an almost complete loss of AHR expression, increased basal protein levels of OCT4 and very low expression of neuronal markers βIII-tubulin and Tau, consistent with the results presented above (Figure [6A](#F6){ref-type="fig"}). Similar data were obtained using two different shRNA molecules and two different pools of NTERA cells, excluding potential off-target effects in the observed phenotype. Restoring AHR expression in NTERA-sh 3′UTR cells by transient transfection mimicked the effects induced by RA with respect to the expression of OCT4 and the neuronal differentiation markers βIII-tubulin and Tau (Figure [6A](#F6){ref-type="fig"}). Control experiments showed that AHR produced from the transfected plasmid was transcriptionally active in NTERA-sh 3′UTR cells based on the induction of its canonical target gene *CYP1A1* (Figure [6B](#F6){ref-type="fig"}). In agreement with data shown above, rescuing AHR expression, in absence of RA treatment, increased the levels of *NANOG Alu*-T1 and *Alu*-T2 (Figure [6C](#F6){ref-type="fig"} and [D](#F6){ref-type="fig"}) and repressed the mRNA expression of *OCT4* and *NANOG* (Figure [6E](#F6){ref-type="fig"} and [F](#F6){ref-type="fig"}) in NTERA-sh 3′UTR cells. Moreover, transient transfection of AHR in wild-type NTERA cells further increased the levels of *NANOG Alu*-derived transcripts (Figure [6C](#F6){ref-type="fig"} and [D](#F6){ref-type="fig"}) and strongly repressed *OCT4* and *NANOG* mRNAs (Figure [6E](#F6){ref-type="fig"} and [F](#F6){ref-type="fig"}). Altogether, these results provide evidences that transcripts produced from *Alu* elements located upstream of *NANOG* and *OCT4* might be involved in controlling the expression of these genes during differentiation of carcinoma cells.

![Rescuing AHR expression in AHR knockdown cells restores the expression of *NANOG Alu*-derived transcripts and represses *OCT4* and *NANOG*. (**A**) NTERA wild-type cells were retrovirally transduced to stably express a shRNA directed against the 3′UTR of the human *AHR*. The resulting NTERA-sh 3′UTR cell line was left untreated (UT), treated with 1 μM RA for 72 h (RA) or transfected with a human AHR expression vector (AHR). Total protein extracts were examined for AHR, OCT4, βIII-tubulin and Tau expression by immunoblotting. NTERA-wt cells were also analyzed in parallel experiments. β-Actin was used to normalize protein expression. (**B**) The expression of the AHR target gene *CYP1A1* was determined by RT-qPCR. (**C**--**F**) NTERA-wt and NTERA-sh 3′UTR cells were treated as above and the levels of *NANOG Alu*-T1 (C), *NANOG Alu*-T2 (D), *OCT4* mRNA (E) and *NANOG* mRNA (F) quantified by RT-qPCR. *GAPDH* mRNA was used to normalize gene expression (ΔCt) and 2^−ΔΔCt^ to calculate variations with respect to control or untreated conditions. Panel A: *n* = 4, two technical replicates in two biological replicates; panels B--F: *n* = 6 two technical replicates in three biological replicates. \**P* \< 0.05, \*\**P* \< 0.01 and \*\*\**P* \< 0.001. Data are shown as mean ± SD.](gkw095fig6){#F6}

Transcription of the *NANOG Alu* from its RNA polIII promoter represses *OCT4* and *NANOG* in absence of RA {#SEC3-6}
-----------------------------------------------------------------------------------------------------------

We next considered the possibility that the transcripts produced from the *NANOG* and *OCT4 Alus* could regulate the expression of their respective genes in absence of RA. To do that, each *Alu* element was cloned in a promoter-less plasmid (pUC57) to allow transcription from its internal RNA polIII promoter (Figure [3B](#F3){ref-type="fig"}, [A](#F3){ref-type="fig"} and [B](#F3){ref-type="fig"} boxes). We first confirmed by RT-qPCR that the *OCT4* and *NANOG-Alu* constructs specifically expressed the corresponding *Alu*-T and *Alu*-T1 and *Alu*-T2 transcripts, respectively (Figure [7A](#F7){ref-type="fig"}). Remarkably, whereas transfection of the *OCT4-Alu* did not repress *OCT4* nor *NANOG* in NTERA-wt cells, expression of the *NANOG-Alu* efficiently repressed the mRNA levels of both genes (Figure [7B](#F7){ref-type="fig"} and [C](#F7){ref-type="fig"}), suggesting that transcripts produced from the *NANOG Alu* could potentially act in *cis* and *trans* to regulate *NANOG* and *OCT4* expression. To provide additional support for the role of *NANOG Alu*-derived transcripts in regulating *OCT4* and *NANOG*, we have introduced site-specific mutations in the XRE sites and in the A and B boxes for AHR and RNA polIII binding, respectively (Figure [7D](#F7){ref-type="fig"}). The selected mutations were highly effective in blocking *NANOG Alu* transcription from its internal RNA polIII promoter since the levels of *NANOG Alu*-T1 and *Alu*-T2 transcripts were largely reduced in NTERA-wt cells transfected with the promoter-less pUC57 vector harboring the XREmut, A + Bmut or XRE/A + Bmut sequences (Figure [7E](#F7){ref-type="fig"}). Notably, mutation of the XRE sites (XREmut), the A and B boxes (A + Bmut) or both (XREmut/A + B mut) significantly blocked the ability of the *NANOG Alu* to repress the mRNA expression of *NANOG* and *OCT4* (Figure [7F](#F7){ref-type="fig"} and [G](#F7){ref-type="fig"}), confirming that, in the absence of transcription from the *NANOG Alu*, the repressive mechanism was markedly impaired. Control experiments excluded the possibility that the effects produced by *NANOG* and *OCT4 Alus* were due to changes in AHR protein levels (Supplementary Figure S6E). In addition, repression of *NANOG* and *OCT4* was AHR dependent since the *NANOG Alu* did not have a significant effect in NTERA-sh cells (Supplementary Figure S7A,B). Importantly, AHR- and RNA polIII-dependent transcription of the *NANOG Alu* may not have a general impact on pluripotency genes since it did not alter the mRNA levels of the reprogramming factor *SOX2* ([@B39]) (Supplementary Figure S7C), the stem-cell factor and OCT4 regulator *LIN28* ([@B40]) (Supplementary Figure S7D) or the pluripotency-inducing factor *NR5A2* ([@B41]) (Supplementary Figure S7E). Moreover, even though the 3′UTR regions of *LIN28* and *NR5A2* have significant sequence homology with *NANOG Alu*-derived transcripts, their mRNA expression did not change by the *NANOG Alu* in NTERA-wt cells, further suggesting a specific effect on the *NANOG* mRNA.

![*NANOG Alu* represses *NANOG* and *OCT4* expression in the absence of RA through AHR and RNA polIII. (**A**) *NANOG* and *OCT4 Alu*s were individually transfected in NTERA-wt cells and the levels of *NANOG Alu*-T1, *Alu*-T2 and *OCT4 Alu*-T transcripts determined by RT-qPCR. (**B** and **C**) A promoter-less pUC57 expression vector containing the *NANOG* or *OCT4 Alus* was transfected in NTERA-wt cells and the mRNA levels of *NANOG* and *OCT4* determined by RT-qPCR. RA was used as positive control. (**D**) Mutations introduced in the *NANOG Alu* to inactivate the XRE sites for AHR binding (cyan), the A (yellow) and B (green) boxes for RNA polIII or a combination of all of them. (**E**) *NANOG Alu* mutant constructs for AHR binding (XREmut), RNA polIII binding (A + Bmut) or both (XRE/A + Bmut) were transfected in NTERA-wt cells and the levels of *NANOG Alu*-T1 and *Alu*-T2 quantified by RT-qPCR. (**F** and **G**) Mutant constructs for the XRE sites and/or the A and B boxes in the *NANOG Alu* were cloned in the promoter-less pUC57 plasmid and transfected in NTERA-wt cells. Wild-type *NANOG Alu* (wt) and the empty plasmid (EV) were also transfected as controls. The mRNA levels of *NANOG* (F) and *OCT4* (G) were analyzed by RT-qPCR. Wild-type *NANOG Alu* (wt) and the empty plasmid (EV) were used as experimental controls. *GAPDH* mRNA was used to normalize gene expression (ΔCt) and and 2^−ΔΔCt^ to calculate variations with respect to control or untreated conditions. Panels A-C; E-G: n = 6, two technical replicates in three biological replicates. \**P* \< 0.05, \*\**P* \< 0.01 and \*\*\**P* \< 0.001. Data are shown as mean ± SD.](gkw095fig7){#F7}

We then decided to analyze if AHR could also modulate *OCT4* and *NANOG* expression and the levels of *NANOG Alu*-derived transcripts in non-transformed human ES cells. To do that, we used H9 human ES cells that were either differentiated with RA ([@B42],[@B43]) or transiently transfected with a sh-AHR against AHR. H9 cells treated with RA significantly increased their AHR protein levels while markedly decreased their OCT4 and NANOG protein content (Supplementary Figure S8A). Downmodulation of pluripotency factors OCT4 and NANOG likely arose from a significant reduction in their mRNA levels after RA treatment (Supplementary Figure S8B). Importantly, RA treatment largely increased the expression of the *Alu*-T1 and *Alu*-T2 transcripts derived from the *NANOG Alu* while moderately enhanced the amount of the *OCT4 Alu-T* transcript (Supplementary Figure S8C). Next, H9 cells were transiently transfected with the same sh-AHR construct used to generate the stable NTERA-sh cell line analyzed above. AHR knockdown produced a significant increase in the protein levels of both OCT4 and NANOG as compared to wild-type H9 cells (Supplementary Figure S9A). Consistently, AHR downmodulation upregulated the mRNA levels of both genes in H9 cells (Supplementary Figure S9B). Furthermore, a transient reduction in AHR expression decreased the levels of *NANOG Alu-*T1 and *Alu-*T2 transcripts without having a significant effect in the *OCT4 Alu*-T transcript (Supplementary Figure S9C). Therefore, AHR appears to be able to regulate pluripotency factors OCT4 and NANOG and the expression of transcripts derived from the NANOG and OCT4 Alus not only in tumorigenic NTERA cells but also in untransformed H9 human ES cells.

*NANOG* and *OCT4* repression by *Alu*-derived transcripts involves the miRNA machinery {#SEC3-7}
---------------------------------------------------------------------------------------

Previous studies have shown that the component of the miRNA pathway Microprocessor (DGCR8 and DROSHA) can bind transcripts produced from *Alu* and LINE-1 (long interspersed element-1) retrotransposons ([@B25]). It is also known that small non-coding RNAs produced by DICER/AGO3 from *Alu*s containing the DR2 motif can modulate the proliferation of human stem cells ([@B44]). A DR2 element is defined as a 6-bp direct repeat of the retinoid acid receptor (RAR) binding site spaced by 2 nt ([@B44]). Based on these previous studies, we investigated whether the miRNA machinery was involved in the *Alu*-dependent regulation of *NANOG* and *OCT4*. First, we treated NTERA-wt cells with the RISC (RNA-induced silencing complex) inhibitor ATA (aurintricarboxylic acid) ([@B45]) and found that ATA significantly prevented the repression of *NANOG* and *OCT4* caused by RA (Figure [8A](#F8){ref-type="fig"} and [B](#F8){ref-type="fig"}). Consistent with the implication of *NANOG Alu*-derived transcripts in the mechanism, inhibition of the miRNA machinery by ATA also increased the levels of *NANOG Alu*-T1 and *NANOG Alu*-T2 in NTERA-wt cells treated with RA (Figure [8C](#F8){ref-type="fig"} and [D](#F8){ref-type="fig"}). Next, we transfected plasmids expressing dominant-negative forms of DROSHA and DGCR8 in NTERA-wt cells and observed that blockade of these proteins rescued the repression of *NANOG* and *OCT4* produced by the *NANOG Alu* in absence of RA (Figure [8E](#F8){ref-type="fig"} and [F](#F8){ref-type="fig"}). Control experiments confirmed that dominant-negative forms of DROSHA and DGCR8 efficiently inhibited the miRNA pathway based on the accumulation of the pre-miR-24-1 (Supplementary Figure S7F). Collectively, these data suggest that transcripts produced from the *NANOG Alu* may act through the miRNA pathway to control *NANOG* and *OCT4* expression, and that such process requires miRNA pathway components RISC and Microprocessor.

![RISC inhibition and microprocessor knockdown rescues *NANOG* and *OCT4* expression likely through loading of *NANOG Alu*-derived transcripts into AGO2. (**A** and **B**) NTERA-wt cells were left untreated (UT), treated with 25 μM ATA (aurintricarboxylic acid) or with 1 μM RA + 25 μM ATA and the expression of *NANOG* (A) and *OCT4* (B) determined as above. (**C** and **D**) NTERA-wt cells were left untreated (UT), treated with 25 μM ATA or with 1 μM RA + 25 μM ATA and the expression of *NANOG Alu*-T1 (C) and *Alu*-T2 (D) determined by RT-qPCR. The oligonucleotides used are indicated in Supplementary Table S1. (**E** and **F**) The *NANOG Alu* was transfected in NTERA-wt cells with or without dominant-negative forms of DROSHA or DGCR8 and their effects on *NANOG* (E) and *OCT4* (F) expression analyzed by RT-qPCR. (**G**) RNA was extracted from NTERA-wt cells and RNA immunoprecipitations (RIP) for *NANOG Alu*-T1 and *Alu*-T2 and *OCT4 Alu*-T transcripts performed using an anti-AGO2 antibody. RIP was quantified by qPCR using the oligonucleotides indicated in Supplementary Table S1. *GAPDH* mRNA was used to normalize gene expression (ΔCt) and 2^−ΔΔCt^ to calculate variations with respect to control or untreated conditions. Panels A and B: *n* = 6, two technical replicates in three biological replicates; panels C and D: *n* = 6, two technical replicates in three biological replicates; panels E and F: *n* = 4, two technical replicates in two biological replicates; panel G: *n* = 4, two technical replicates in two biological replicates. \**P* \< 0.05, \*\**P* \< 0.01 and \*\*\**P* \< 0.001. Data are shown as mean ± SD.](gkw095fig8){#F8}

As mentioned above, the DR2 element appears to be relevant for loading *Alu*-derived transcripts into the miRNA machinery via AGO3 ([@B44]). Since the *NANOG Alu* has a DR2 sequence (Figure [3B](#F3){ref-type="fig"}), we next tested whether AGO proteins could bind RNA transcripts produced from the *NANOG and OCT4 Alus*. RIP followed by RT-qPCR showed that *NANOG Alu*-T1 and *Alu*-T2 and *OCT4 Alu*-T transcripts were loaded into the RISC component AGO2, and that loading increased upon differentiation of NTERA-wt cells (Figure [8G](#F8){ref-type="fig"}). Interestingly, cuantitative RNA analysis revealed a very low efficiency of *OCT4 Alu*-T loading into AGO2 even under RA-induced differentiation. Loading of *NANOG Alu*-T1 and *Alu*-T2 transcripts into AGO2 increased with time for at least 48 h after RA treatment (Supplementary Figure S7G).

Certain TEs, including *Alu* retrotransposons, can regulate the generation of miRNAs (e.g. *Let-7*) known to be involved in cellular differentiation ([@B46]). The analysis of pre-miRNA expression revealed that differentiation reduced the levels of pre-*Let-7* and increased pre-*miR-21, pre-miR-424, pre-miR371* and pre-*miR-*141 in NTERA-wt but not in NTERA-sh cells (Figure [9A](#F9){ref-type="fig"}). Interestingly, time course experiments showed that *NANOG Alu*-T1 and *Alu*-T2 transcripts appeared early during differentiation (e.g. 24 h) whereas those pre-miR molecules reached their maximum levels only after 72 h of RA treatment (Figure [9B](#F9){ref-type="fig"}), suggesting that transcription of *NANOG Alu*-derived transcripts probably precedes the accumulation of miRNAs that could cooperate to control the differentiation of NTERA cells.

![*NANOG Alu*-derived transcripts could act through a miRNA mechanism to control *NANOG* and *OCT4* repression during differentiation. (**A**) NTERA-wt and NTERA-sh cells were left untreated (UT) or treated with 1 μM RA for 48 h and the levels of pre-miRs *pre-Let7, pre-miR-21, pre-miR-424, pre-miR-371, pre-miR-141* quantified by RT-qPCR using the oligonucleotides indicated in Supplementary Table S1. (**B**) Both cell lines were treated with 1 μM RA for the indicated times and the levels of *NANOG Alu*-T1 and *Alu*-T2, *pre-Let7, pre-miR-21* and *pre-miR-141* determined by RT-qPCR. (**C**) A *NANOG* 3′UTR-Luc construct and their deletion mutants lacking the homology regions for *NANOG Alu*-T1 (T1 mut), *Alu*-T2 (T2 mut) or both (T1 + T2 mut) were co-transfected with the *NANOG Alu* in NTERA-wt cells. Firefly luciferase activity was measured and normalized by renilla luciferase. Control experiments were done in presence of RA (dashed). (**D**) NTERA-wt and NTERA-sh cells were injected subcutaneously in immunodeficient Swiss nude mice (Charles River) and the tumors formed collected and analyzed by immunohistochemistry using endodermal (pan-cytokeratins and α-fetoprotein), mesodermal (α-smooth muscle actin) and ectodermal (glial fibrilar acidic protein, GFAP) markers. Immunohistochemistry sections were analyzed blinded by eight independent observers and protein expression quantified in a 0--10 scale. Arrowheads indicate positivity areas used to estimate protein expression. (**E**) Scheme of the mechanism proposed for the *Alu*-dependent repression of *NANOG* and *OCT4* during carcinoma cell differentiation. *GAPDH* mRNA was used to normalize gene expression (ΔCt) and 2^−ΔΔCt^ to calculate variations with respect to control or untreated conditions. Panels A and B: *n* = 6, three technical replicates in two biological replicates; panel C: *n* = 4, two technical replicates in two biological replicates; panel D: *n* = 4 mice for each cell line. \**P* \< 0.05, \*\**P* \< 0.01 and \*\*\**P* \< 0.001. Data are shown as mean ± SD.](gkw095fig9){#F9}

These results lead us to consider that *NANOG Alu-*T1 and *Alu*-T2 transcripts, loaded into AGO2, could target complementary sequences in the mRNAs of *NANOG* and *OCT4*. Sequence analysis revealed that *NANOG Alu*-T1 and *Alu*-T2 transcripts were highly homologous to the 3′UTR of *NANOG* and significantly homologous to the 3′UTR of *OCT4* (Supplementary Figure S10A and B). Conditional training analysis for the prediction of RNA secondary structures (CONTRAfold) revealed the optimal conformation of *NANOG Alu*-T1 and *Alu*-T2 transcripts in their homology regions with the 3′UTR of *NANOG* and *OCT4* (Supplementary Figure S10C and D). Importantly, sequence analyses by RepeatMasker (<http://www.repeatmasker.org>) revealed that the 3′UTR of *NANOG* harbors an *AluY* element homologous to *NANOG Alu*-T1 and *Alu*-T2 transcripts. However, the 3′UTR of *OCT4* did not contain *Alu*-derived sequences despite its partial homology with *NANOG Alu*-T1 and *Alu*-T2 (Supplementary Figure S10A,B). Other genes involved in differentiation but not regulated by *Alu*-derived transcripts such as *SOX2* and *NOTCH1* did not contain *Alu*-derived sequences in their 3′UTR regions, nor homology with *NANOG Alu*-T1 and *Alu*-T2. These findings suggested that the *Alu* present in the 3′UTR region of *NANOG* could interact with *NANOG Alu*-derived transcripts to repress *NANOG* expression in differentiated cells.

To analyze if *NANOG Alu* could regulate *NANOG* 3′UTR, we cloned the wild-type *NANOG* 3′UTR and its mutant forms lacking the homology regions for *NANOG Alu*-T1 and *Alu*-T2 transcripts in a luciferase reporter vector (Supplementary Figure S7H). Transfection of NTERA-wt cells with *NANOG Alu* in absence of RA repressed the activity of the wild-type *NANOG* 3′UTR-Luc construct (Figure [9C](#F9){ref-type="fig"}). However, the *NANOG Alu* was unable to repress the activity of *NANOG* 3′UTR-Luc mutants lacking the homology regions for *Alu*-T1, *Alu*-T2 or both transcripts (Figure [9C](#F9){ref-type="fig"}). These data led us to speculate that *NANOG Alu* might regulate *NANOG* and *OCT4* at the mRNA level through the miRNA pathway. Consistent with this hypothesis, bioinformatic studies have suggested that *Alu* sequences located in the 3′UTR region of certain mRNAs can be recognized by miRNAs to regulate target gene expression ([@B49]).

AHR knockdown increases the formation of undifferentiated teratomas {#SEC3-8}
-------------------------------------------------------------------

We finally decided to validate AHR as a differentiation factor in human carcinoma cells using an *in vivo* teratoma assay. NTERA-wt and NTERA-sh cells were xenografted in immunocompromised Swiss mice and the teratomas formed analyzed for the presence of the three embryonic layers ([@B39]). Using this assay, we found that NTERA-wt cells generated teratomas containing endodermal (pan-cytokeratin and α-fetoprotein), mesodermal (α-smooth muscle actin) and ectodermal (glial fibrilar acidic protein, GFAP) embryonic layers (Figure [9D](#F9){ref-type="fig"}). Teratomas formed by NTERA-sh cells had significantly higher expression of endodermal, mesodermal and ectodermal markers than NTERA-wt cells (Figure [9D](#F9){ref-type="fig"}), suggesting that AHR depletion led to a more undifferentiated phenotype and an increased ability to differentiate *in vivo*. It is reasonable to assume that such properties of NTERA-sh cells might be due, at least in part, to their increased expression of pluripotency factors NANOG and OCT4. Notably, our hypothesis is in agreement with recent studies showing that *in vivo* reprogramming induces undifferentiated teratomas with increased expression of NANOG ([@B50]), and that OCT4 has a major role in reprogramming and in the generation of iPS cells ([@B51]).

DISCUSSION {#SEC4}
==========

TEs, including LINEs, SINEs and human *Alus*, are widespread in mammalian genomes and, although their contribution to genome evolution and dynamics is now generally accepted, very limited knowledge is available regarding their contribution to gene regulation and cell function ([@B2],[@B52]). *Alu* retrotransposons derive from the 7SL RNA and are the most abundant TEs in the Human Genome. Among the different *Alu* lineages known, some ancient genomic *AluS* contain an active core sequence in terms of retrotransposition ability ([@B17]). In addition, it has been suggested that they could be active in somatic tissues as the human brain ([@B53],[@B54]). Furthermore, there is an increasing interest in identifying *Alu* elements whose activation could contribute to human disease, such as that inserted into the ANRIL long non-coding RNA ([@B7]).

In this study, we have presented data suggesting that the dioxin receptor AHR regulates the transcription of *Alu* elements located in the upstream promoter regions of the pluripotency genes *NANOG* and *OCT4*, and that *Alu*-derived transcripts probably repress the expression of both genes in differentiated carcinoma cells possibly through the miRNA pathway. Our study therefore integrates the activation of specific *Alu* elements in the control of important cellular functions such as differentiation and pluripotency.

Here, we demonstrate that AHR acts as a differentiation factor in human embryonic teratocarcinoma cells because its stable knockdown led to a basal undifferentiated phenotype that made cells unresponsive to RA-induced neuronal differentiation. Furthermore, differentiation increased the cellular levels of AHR and promoted its nuclear translocation, thus suggesting increased transcriptional activity of this receptor. The role of AHR in differentiation is also supported by *in vivo* experiments, as teratomas produced by AHR-depleted NTERA cells were more undifferentiated than those from AHR-expressing NTERA cells. These results are consistent with the activation of AHR during differentiation of mouse ES cells ([@B31]) and with the inhibitory role of mouse AHR in epithelial-to-mesenchymal transition ([@B21]) and in melanoma primary tumorigenesis and metastasis ([@B20]).

AHR has been extensively characterized as a transcription factor that binds the promoter region of xenobiotic-related and xenobiotic-unrelated genes ([@B55]). It is remarkable that AHR can also interact with specific repetitive retrotransposon sequences such as the murine B1-SINE to trigger the activation of a genomic insulator eventually able to modulate gene expression ([@B14]). Binding to TEs appears to be a conserved property of AHR, as we show here that it can also directly binds to human *AluS* retrotransposons located in the promoter region of the pluripotency genes *OCT4* and *NANOG*. However, a complex interplay between AHR binding and *AluS* sequences seems to occurs, since differentiation recruits AHR to the *NANOG Alu* while releasing it from the *OCT4 Alu*. One possible explanation for these results is that the increase in nuclear AHR that takes place during differentiation could shift the receptor from the *OCT4* to the *NANOG Alu*, inducing at the same time the co-recruitment of OCT4 to the *NANOG Alu*. This would imply that AHR can cooperate with OCT4 in repressing *NANOG* expression and, thus, integrates this receptor into the proposed 'pluripotency core regulatory circuitry' of transcription factors that also includes SOX2 and that governs differentiation in human and mouse ES cells ([@B56]). In fact, AHR activation by its non-toxic ligand FICZ produced a robust binding of OCT4 to the *NANOG Alu* in absence of RA.

Notably, the repression of *Alu*-containing *OCT4* and *NANOG* genes in differentiated NTERA cells is AHR dependent based on the lack of response shown by AHR-depleted cells, and appears to be specific since it does not take place in other examined *Alu*-containing pluripotency genes such as *SOX2, NOTCH1, MYC* and *KLF4*. Importantly, the repression process seemed to require the synthesis of non-coding RNA molecules since blockade of RNA polymerase III restored *OCT4* and *NANOG* expression in an AHR-dependent manner. Notably, and as RNA polIII may transcribe 7SL RNAs and other non-coding sequences ([@B59]), we speculated that transcripts derived from the *NANOG* and *OCT4 Alus* could participate in the repression of both genes. Indeed, RNAseq and RT-qPCR experiments revealed that differentiation of NTERA cells increased the levels of transcripts derived from *NANOG* and *OCT4 Alus*, being predominant those synthesized from the *NANOG Alu*. In agreement with the gene expression data, transcription of these *Alu* elements is AHR dependent because their levels are upregulated by AHR knockdown in RA differentiated cells and increased by AHR rescue in RA-untreated cells. Such AHR-dependent mechanism regulating the expression of *OCT4, NANOG* and *NANOG Alu*-derived transcripts may be operative in non-transformed human cells since RA treatment and AHR knockdown reproduced in human H9 ES cells the same regulatory pattern to that observed in embryonic carcinoma NTERA cells. One important observation is that the *Alu* retrotransposons located in *NANOG* and *OCT4* promoters have a high degree of sequence specificity, not been detectable at additional locations in the Human Genome. This property most likely determines that *NANOG*- and *OCT4 Alu*-derived transcripts have full sequence identity and full homology only to the chromosomal regions where their respective *Alus* are located and from which they are transcribed. Another relevant finding from this study is that expression of these *Alu* elements, by themselves, could regulate *NANOG* and *OCT4* during carcinoma cell differentiation. We consider this result relevant since a deep transcriptome profiling study has shown that non-coding transcripts derived from long terminal repeats can associate to enhancers of pluripotency related genes ([@B18],[@B60],[@B61]). Nevertheless, the effects of *NANOG* and *OCT4 Alus* in gene repression appear to have a significant degree of specificity regarding not only to the *Alu* element but also their target genes. Indeed, expression of *NANOG Alu* from its endogenous promoter repressed both *NANOG* and *OCT4* mRNAs in absence of a differentiation stimulus. In contrast, expression of *OCT4 Alu* does not significantly affect either gene under the same experimental conditions. Additionally, whereas *NANOG Alu* most likely regulates the *NANOG* gene in *cis*, its effects on the *OCT4* gene could be done in *trans*. Such mechanism would resemble the one recently proposed for the long non-coding RNA ANRIL that regulates atherosclerosis genes in *trans* by means of an *Alu* element present in its sequence ([@B7]). Alternatively, the *NANOG Alu* could act on *OCT4* by an indirect mechanism involving signaling through *NANOG* itself. Nonetheless, this possible functional connection between *NANOG* and *OCT4* again supports the 'pluripotency core regulatory circuitry' mentioned above that would also include AHR ([@B56]). Finally, expression of *NANOG Alu* efficiently repressed *NANOG* and *OCT4* but not other genes containing similar *Alu* elements such as *SOX2, LIN28* and *NR5A2*. Although we cannot rule out at present time that other *Alu loci* dispersed in the Human Genome might contribute to the generation of additional ncRNAs, when combined with the ChIP data, our results strongly support that *NANOG* and *OCT4 Alu*-derived transcripts may be involved in the regulation of pluripotency.

Interestingly, recent studies in rice have shown that the plant DICER homolog DICER-like 3 can use TE RNAs to generate small interfering RNAs (siRNA) with the potential to change some agricultural traits of the plant ([@B62]). Similarly, in human cells, the Microprocessor can interact and process transcripts derived from *Alus* and LINE-1 to regulate retrotransposition, although it is not clear whether processed RNAs give rise to functional miRNAs that might help to regulate the expression of cellular genes ([@B25]). Notably, we found that chemical inhibition of the miRNA pathway by ATA not only rescued *OCT4* and *NANOG* repression in differentiated cells but also increased the expression of *NANOG Alu*-T1 and *Alu*-T2 and *OCT4 Alu*-T transcripts. Furthermore, dominant negative forms of Microprocessor components DROSHA and DGCR8 also blocked the repression of *NANOG* and *OCT4* induced by the *NANOG Alu* in absence of RA. Intriguingly, the interaction between the miRNA pathway and transcripts derived from retrotransposons could be functionally conserved since inhibition of the Microprocessor also increased the levels of LINE1-derived transcripts and the expression of their target genes ([@B25]).

Although the mechanism by which *NANOG* and *OCT4 Alu*-derived transcripts may regulate gene expression require further experimentation, we speculate that it probably involves the interaction of *Alu*-derived transcripts with the 3′UTR region of the *NANOG* and *OCT4* mRNAs. Several experiments support this model. First, *NANOG Alu*-T1 and *Alu*-T2 and *OCT4 Alu*-T transcripts are loaded into the RISC component AGO2 and such loading significantly increased with differentiation of NTERA cells. Second, a marked sequence similarity exists between *NANOG Alu*-T1 and *Alu*-T2 transcripts and the 3′UTR region of *NANOG* and *OCT4* mRNAs. Third, the *NANOG Alu* was able to regulate the 3′UTR of *NANOG* but only if the homology sequences for the *Alu*-T1 and *Alu*-T2 transcripts remained intact. Finally, the levels of miRNAs involved in differentiation such as *Let7* and *miR141* increased with time by RA treatment in NTERA-wt but not in NTERA-sh cells and, interestingly, the expression of *NANOG Alu*-T1 and *Alu*-T2 preceded the accumulation of *Let7* and *miR141*. It will be interesting to address the processing and identity of these *Alu*-derived transcripts and the mechanisms by which they probably interact with the 3′UTR regions of both genes. Our working model proposing that the interaction of *Alu* derived-transcripts with 3′UTRs could regulate gene expression through the miRNA pathway has been also considered in previous studies. Indeed, bioinformatic analyses have shown that certain small RNAs have the potential to target *Alu*-complementary sequences located in the 3′UTR of human mRNAs ([@B49]). Moreover, the FANTOM4 project has revealed that retrotransposons located in the 5′ end of mouse and human protein coding genes (as is the case for *NANOG* and *OCT4 Alus*) have the potential to be transcribed into non-coding RNAs. Importantly, this study also indicates that a large fraction of the expressed transcripts that contain retrotransposon complementary sequences in their 3′UTRs have lower expression levels than retrotransposon-free transcripts ([@B63]). Accordingly, we have found that the *NANOG* mRNA contains an *AluY* element in its 3′UTR that is highly homologous with ncRNAs generated from the *AluSx* located in the *NANOG* promoter. However, the 3′UTR of the *OCT4* mRNA has only partial homology with *NANOG Alu*-derived transcripts, suggesting the existence of subtle differences in regulation between both genes.

In sum, we propose that AHR activates the transcription of *Alu* retrotransposons located in the *NANOG* and *OCT4* upstream promoter regions in differentiated human carcinoma cells. Non-coding RNA transcripts produced from these *Alus* could repress *NANOG* and *OCT4* expression probably through the miRNA pathway (Figure [9E](#F9){ref-type="fig"}). *OCT4* and *NANOG* repression in differentiated cells is AHR and RNA polIII dependent and, notably, the expression of the *NANOG Alu* is able to repress both genes in the absence of a differentiating stimuli. This regulatory mechanism could be relevant for normal and tumor cell growth and dissemination. Moreover, the results included in this study reveal how fixed TEs can participate in Human Genome regulation by a novel mechanism involving non-coding RNAs and the miRNA pathway (Figure [9E](#F9){ref-type="fig"}).
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